Menu
Search
|

Menu

Close
X

Momenta Pharmaceuticals Inc MNTA.OQ (NASDAQ Stock Exchange Global Select Market)

14.53 USD
+0.38 (+2.69%)
As of 4:00 PM EDT
chart
Previous Close 14.15
Open 14.15
Volume 272,848
3m Avg Volume 340,433
Today’s High 14.84
Today’s Low 13.96
52 Week High 32.15
52 Week Low 9.56
Shares Outstanding (mil) 98.51
Market Capitalization (mil) 1,393.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
76
FY17
139
FY16
110
EPS (USD)
FY18
-2.296
FY17
-1.219
FY16
-0.311
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
40.53
Price to Sales (TTM)
vs sector
18.44
8.82
Price to Book (MRQ)
vs sector
3.02
4.66
Price to Cash Flow (TTM)
vs sector
--
28.75
Total Debt to Equity (MRQ)
vs sector
0.00
17.43
LT Debt to Equity (MRQ)
vs sector
0.00
13.74
Return on Investment (TTM)
vs sector
-39.34
12.30
Return on Equity (TTM)
vs sector
-42.16
13.41

EXECUTIVE LEADERSHIP

Craig Wheeler
President, Chief Executive Officer, Director, Since 2018
Salary: $750,000.00
Bonus: --
Michelle Robertson
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Young Kwon
Senior Vice President, Corporate Development and Strategy, Since 2015
Salary: --
Bonus: --
Santiago Arroyo
Senior Vice President, Development and Chief Medical Officer, Since 2017
Salary: $257,231.00
Bonus: --
Bruce Downey
Independent Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

301 Binney St
CAMBRIDGE   MA   02142-1030

Phone: +1617.4919700

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

SPONSORED STORIES